Restoration of lymphatic function in postsurgical lymphedema with lymph node transfer
通过淋巴结转移恢复术后淋巴水肿的淋巴功能
基本信息
- 批准号:9185953
- 负责人:
- 金额:$ 19.13万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-12-01 至 2017-11-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdjuvant TherapyAffectAnimalsAntibody ResponseArchitectureAxillary Lymph Node DissectionB-LymphocytesBiologyBreast Cancer TreatmentBreast cancer metastasisCancer BiologyChronicClinicalClinical ResearchDefectDendritic CellsDevelopmentDiphtheria ToxinDiseaseDisease ManagementFunctional disorderGrowthImmuneImmune System DiseasesImmune System and Related DisordersImmune responseImpairmentImplantIncidenceInfectionInfiltrationInflammatoryInjuryInterleukin-6KnowledgeLeadLimb structureLymph Node DissectionsLymph node excisionLymphaticLymphatic SystemLymphatic vesselLymphedemaLymphoid TissueMalignant NeoplasmsMammary NeoplasmsMassageMethodsMicroscopicMissionModelingMolecularMorbidity - disease rateMusNatural regenerationNeoplasm MetastasisObesityOperative Surgical ProceduresPathway interactionsPatientsPlayPositioning AttributeProcessRadiationReactionRecurrenceRegulatory T-LymphocyteReportingResolutionRiskRisk FactorsRoleSiteSourceSurgical ManagementSwellingT cell responseT-LymphocyteTailTechniquesTestingTimeTissuesTumorigenicityUnited States National Institutes of Healthaging populationbasecancer complicationcancer therapyclinically relevantdesignenvironmental changeexperimental studyhigh riskimmune functionimmunoregulationimprovedimproved outcomeinnovationlymph nodeslymphatic circulationmacrophagemalignant breast neoplasmmigrationmouse modelmultidisciplinarynovelpalliativepatient populationpreventpublic health relevanceresponse to injuryrestorationtumortumor growthtumorigenic
项目摘要
DESCRIPTION (provided by applicant): This proposal is significant because we aim to develop novel treatments for lymphedema, a common and morbid complication of cancer treatment that results in chronic swelling, recurrent infections, and immune dysfunction. Recent clinical studies have reported decreased swelling and symptomatic relief after lymph node transfer (LNT) to the affected limb. To study the mechanisms of this process, we have developed a mouse model of LNT and have shown that the lymphatic vessels of the lymph node spontaneously reconnect with the lymphatics of the recipient site thereby restoring lymphatic circulation. However, although these results are promising, it remains unclear if immunologic function is restored after LNT. This gap in our knowledge is important because understanding the mechanisms by which LNT regulates immune function and microenvironmental changes is a necessary step for improving these outcomes. Our proposed study will address this gap and will therefore break new ground in the treatment of lymphedema. Our approach is innovative because we have developed an inducible mouse model of lymphedema in which tissue lymphatics can be selectively ablated using diphtheria toxin. This enables us to study immune function after LNT in a clinically relevant model and test the central hypothesis that lymphatic regeneration after LNT restores immune function and promotes resolution of tumorigenic microenvironmental changes. Aim 1: Determine how LNT restores immune function. This aim will test the hypothesis that innate and adaptive immune function is restored after LNT. The rationale for these studies is based on the fact that patients who have undergone lymph node dissection or suffer from lymphedema have impaired antibody response and are at increased risk for infections. Aim 2: Determine how LNT regulates lymphatic injury induced microenvironmental changes and tumor recurrence. This aim will test the hypothesis that LNT decreases activation of tumorigenic microenvironmental changes known to occur after lymphatic injury. This hypothesis is based on the rationale that 1) Patients with breast cancer are at high risk for loco-regional recurrence; 2) Lymphatic injury increases expression of tumorigenic pathways including interleukin 6 as well as macrophages and Treg infiltration; and 3) Previous animal studies have shown that lymphatic injury increases the growth/metastasis of breast cancers. We will test our mouse model of LNT together with microscopic orthotopic and heterotopic breast tumor implants to determine how restoration of immune responses by LNT regulate growth of local recurrence or development of a new primary cancer. As a result of these studies, we expect to further our understanding of the mechanisms by which lymphatic injury regulates tumor growth/spread and how these changes are modulated by LNT. At the conclusion of the proposed study we expect to understand the mechanisms that regulate impaired immune function and promote tumorigenic environmental changes after lymphatic injury and how these responses are altered by LNT. These studies are therefore not only important not to patients with lymphedema but will also increase our general understanding of how the lymphatic system can regulate tumor growth.
描述(由申请人提供):该提案意义重大,因为我们的目标是开发治疗水肿的新疗法,水肿是癌症治疗的常见和病态并发症,导致慢性肿胀,复发性感染和免疫功能障碍。最近的临床研究报告称,淋巴结转移(LNT)到患肢后,肿胀减轻,症状缓解。为了研究这一过程的机制,我们开发了LNT小鼠模型,并显示淋巴结的淋巴管自发地与受体部位的淋巴管重新连接,从而恢复淋巴循环。然而,尽管这些结果是有希望的,但仍不清楚LNT后免疫功能是否恢复。我们知识中的这一差距很重要,因为了解LNT调节免疫功能和微环境变化的机制是改善这些结果的必要步骤。我们提出的研究将解决这一差距,因此将开辟新的地面治疗水肿。我们的方法是创新的,因为我们已经开发了一种可诱导的小鼠水肿模型,其中可以使用白喉毒素选择性地消融组织炎症。这使我们能够在临床相关模型中研究LNT后的免疫功能,并测试LNT后淋巴再生恢复免疫功能并促进致瘤微环境变化的解决的中心假设。目的1:确定LNT如何恢复免疫功能。这一目标将检验先天性和适应性免疫功能在LNT后恢复的假设。这些研究的基本原理是基于这样一个事实,即接受淋巴结清扫术或患有水肿的患者抗体应答受损,感染风险增加。目的2:确定LNT如何调节淋巴损伤诱导的微环境变化和肿瘤复发。这一目标将测试的假设,即LNT减少激活的致瘤微环境的变化,已知发生在淋巴损伤。该假设基于以下基本原理:1)乳腺癌患者局部复发风险高; 2)淋巴损伤增加了致瘤途径的表达,包括白细胞介素6以及巨噬细胞和Treg浸润; 3)先前的动物研究表明,淋巴损伤增加了乳腺癌的生长/转移。我们将测试我们的LNT小鼠模型以及显微镜原位和异位乳腺肿瘤植入物,以确定LNT如何恢复免疫应答,调节局部复发或新原发性癌症的发展。作为这些研究的结果,我们期望进一步了解淋巴损伤调节肿瘤生长/扩散的机制以及LNT如何调节这些变化。在拟议的研究的结论,我们希望了解的机制,调节受损的免疫功能,促进淋巴损伤后的致瘤环境变化,以及如何改变这些反应LNT。因此,这些研究不仅对水肿患者很重要,而且还将增加我们对淋巴系统如何调节肿瘤生长的一般理解。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Babak J Mehrara其他文献
Babak J Mehrara的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Babak J Mehrara', 18)}}的其他基金
Role of epidermis in regulating inflammatory skin manifestations of post-surgical lymphedema
表皮在调节术后淋巴水肿炎症性皮肤表现中的作用
- 批准号:
10606927 - 财政年份:2022
- 资助金额:
$ 19.13万 - 项目类别:
Molecular mechanisms of age-related lymphatic dysfunction
年龄相关淋巴功能障碍的分子机制
- 批准号:
10538995 - 财政年份:2022
- 资助金额:
$ 19.13万 - 项目类别:
Molecular mechanisms of age-related lymphatic dysfunction
年龄相关淋巴功能障碍的分子机制
- 批准号:
10665795 - 财政年份:2022
- 资助金额:
$ 19.13万 - 项目类别:
Mechanisms of fibrosis and lymphatic dysfunction in post-surgical lymphedema
术后淋巴水肿纤维化和淋巴功能障碍的机制
- 批准号:
8532029 - 财政年份:2012
- 资助金额:
$ 19.13万 - 项目类别:
Mechanisms of fibrosis in post-surgical lymphedema
术后淋巴水肿纤维化的机制
- 批准号:
10063531 - 财政年份:2012
- 资助金额:
$ 19.13万 - 项目类别:
Mechanisms of fibrosis and lymphatic dysfunction in post-surgical lymphedema
术后淋巴水肿纤维化和淋巴功能障碍的机制
- 批准号:
8372995 - 财政年份:2012
- 资助金额:
$ 19.13万 - 项目类别:
Mechanisms of fibrosis and lymphatic dysfunction in post-surgical lymphedema
术后淋巴水肿纤维化和淋巴功能障碍的机制
- 批准号:
8695460 - 财政年份:2012
- 资助金额:
$ 19.13万 - 项目类别:
Mechanisms of fibrosis and lymphatic dysfunction in post-surgical lymphedema
术后淋巴水肿纤维化和淋巴功能障碍的机制
- 批准号:
9094645 - 财政年份:2012
- 资助金额:
$ 19.13万 - 项目类别:
相似海外基金
Countering sympathetic vasoconstriction during skeletal muscle exercise as an adjuvant therapy for DMD
骨骼肌运动期间对抗交感血管收缩作为 DMD 的辅助治疗
- 批准号:
10735090 - 财政年份:2023
- 资助金额:
$ 19.13万 - 项目类别:
The ESCAPE clinical trial of circulating tumor DNA to guide adjuvant therapy in chemo-resistant triple negative breast cancer
循环肿瘤 DNA 指导化疗耐药三阴性乳腺癌辅助治疗的 ESCAPE 临床试验
- 批准号:
494901 - 财政年份:2023
- 资助金额:
$ 19.13万 - 项目类别:
Operating Grants
A Type I Hybrid Effectiveness-Implementation Trial to Evaluate a Navigation-Based Multilevel Intervention to Decrease Delays Starting Adjuvant Therapy Among Patients with Head and Neck Cancer
一项 I 型混合有效性实施试验,用于评估基于导航的多级干预措施,以减少头颈癌患者开始辅助治疗的延迟
- 批准号:
10714537 - 财政年份:2023
- 资助金额:
$ 19.13万 - 项目类别:
Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer
多模式机器学习指导可手术切除结直肠癌的辅助治疗
- 批准号:
10588103 - 财政年份:2023
- 资助金额:
$ 19.13万 - 项目类别:
Efficacy of ethanol adjuvant therapy after resection of malignant soft tissue tumors
恶性软组织肿瘤切除术后乙醇辅助治疗的疗效
- 批准号:
22K09407 - 财政年份:2022
- 资助金额:
$ 19.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of immune response cells and development of novel adjuvant therapy for sublingual immunotherapy
免疫应答细胞的鉴定和舌下免疫治疗新型辅助疗法的开发
- 批准号:
21KK0287 - 财政年份:2022
- 资助金额:
$ 19.13万 - 项目类别:
Fund for the Promotion of Joint International Research (Fostering Joint International Research (A))
Pursuing molecular biomarkers to guide adjuvant therapy for HPV+ head and neck cancers after transoral robotic surgery
寻找分子生物标志物来指导经口机器人手术后 HPV 头颈癌的辅助治疗
- 批准号:
10357120 - 财政年份:2022
- 资助金额:
$ 19.13万 - 项目类别:
Biomarker research using two prospective studies on preoperative and postoperative adjuvant therapy for pancreatic cancer
使用两项关于胰腺癌术前和术后辅助治疗的前瞻性研究进行生物标志物研究
- 批准号:
21K08700 - 财政年份:2021
- 资助金额:
$ 19.13万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Personalized Resistant Starch as an Adjuvant Therapy for Pediatric Inflammatory Bowel Disease
个性化抗性淀粉作为小儿炎症性肠病的辅助治疗
- 批准号:
437315 - 财政年份:2020
- 资助金额:
$ 19.13万 - 项目类别:
Studentship Programs
Tailored adjuvant therapy in POLE-mutated and p53-wildtype early stage endometrial cancer (TAPER)
POLE 突变和 p53 野生型早期子宫内膜癌 (TAPER) 的定制辅助治疗
- 批准号:
435603 - 财政年份:2020
- 资助金额:
$ 19.13万 - 项目类别:
Operating Grants